Naslov
Glucagon-like peptide-1 receptor agonists decrease systolic and diastolic blood pressure in overweight type 2 diabetic patients

Autori
Ljubičić Pavić, Antonela ; Bulum, Tomislav ; Blaslov Kristina ; Boras, Jozo ; Duvnjak, Lea

Izvornik
Diabetologia Croatica (0351-0042) 43 (2014); 57-62

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
type 2 diabetes; exenatide; liraglutide; blood pressure; heart rate

Sažetak
Glucagon-like peptide-1 (GLP-1) agonists are increasingly used in the management of type 2 diabetes (T2DM), but their long-term cardiovascular safety is not yet confirmed. In long-term clinical trials, therapy with GLP-1 receptor agonists has been associated with improvements in blood pressure but also with increases in heart rate (HR). In the present study, we assessed the effects of GLP-1 receptor agonists exenatide and liraglutide on systolic blood pressure (SBP), diastolic blood pressure (DBP) and HR in overweight T2DM patients. A total of 85 overweight T2DM patients were included in the study (43 on exenatide and 42 on liraglutide) and followed up for 13 and 22 months. Treatment with exenatide caused a significant decrease in SBP from 146±20 to140±15 mm Hg (p=0.03), while DBP (from 88±10 to 85±7 mm Hg (p=0.1)) and HR (from 78±10 to 78±12 beats/min (p=0.9)) did not change significantly. Treatment with liraglutide caused a significant decrease in SBP from 145±20 to 135±18 mm Hg (p=0.005) and DBP from 88±8 to 82±8 mm Hg (p<0.001), while HR (from 78±14 to 73±8 beats/min (p=0.2)) did not change significantly. The results of our study suggest that therapy with GLP-1 receptor agonists exenatide and liraglutide may significantly reduce SBP and DBP by 6 to 10 mm Hg.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA